Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Bickel

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 15, 2014
Nephropathy in illicit drug abusers: a postmortem analysisMaike Buettner, Stefan W Toennes, Stefan Buettner, et al.
European Journal of Clinical Pharmacology|December 25, 2009
Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy settingAnnette Haberl, Manfred Moesch, Gabriele Nisius, et al.
European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine|November 9, 2005
Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuseMarkus Bickel, Tilmann Ditting, Henrik Watz, et al.
HIV Clinical Trials|July 10, 2013
Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patientsGiovanni Di Perri, Bruce Green, Glynn Morrish, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2002
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapyJutta K Neuenburg, Hans R Brodt, Brian G Herndier, et al.
Medical Microbiology and Immunology|April 9, 2011
The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypesSaleta Sierra, Nadine Lübke, Hauke Walter, et al.
Therapeutic Drug Monitoring|March 18, 2014
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairmentPavel Khaykin, Peter Kotzerke, Christoph Stephan, et al.
Scandinavian Journal of Infectious Diseases|September 14, 2007
Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophyMarkus Bickel, Stephan Zangos, Thomas Lutz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patientsUlrich A Walker, Markus Bickel, Severine I Lütke Volksbeck, et al.
HIV Clinical Trials|August 9, 2013
Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controlsMarkus Bickel, Christin Lassmann, Imke Wieters, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 15, 2014
Nephropathy in illicit drug abusers: a postmortem analysisMaike Buettner, Stefan W Toennes, Stefan Buettner, et al.
European Journal of Clinical Pharmacology|December 25, 2009
Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy settingAnnette Haberl, Manfred Moesch, Gabriele Nisius, et al.
European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine|November 9, 2005
Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuseMarkus Bickel, Tilmann Ditting, Henrik Watz, et al.
HIV Clinical Trials|July 10, 2013
Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patientsGiovanni Di Perri, Bruce Green, Glynn Morrish, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2002
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapyJutta K Neuenburg, Hans R Brodt, Brian G Herndier, et al.
Medical Microbiology and Immunology|April 9, 2011
The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypesSaleta Sierra, Nadine Lübke, Hauke Walter, et al.
Therapeutic Drug Monitoring|March 18, 2014
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairmentPavel Khaykin, Peter Kotzerke, Christoph Stephan, et al.
Scandinavian Journal of Infectious Diseases|September 14, 2007
Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophyMarkus Bickel, Stephan Zangos, Thomas Lutz, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 8, 2002
Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patientsUlrich A Walker, Markus Bickel, Severine I Lütke Volksbeck, et al.
HIV Clinical Trials|August 9, 2013
Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controlsMarkus Bickel, Christin Lassmann, Imke Wieters, et al.
Pageof 7